ArticleThe South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa2026
A profile of psychotropic medication in bipolar patients of reproductive age.
Article in The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bipolar disorder (BD) is associated with unfavourable reproductive health outcomes. Evidence-based treatment guidelines advocate for reproductive safe prescribing, including family planning, avoidance of teratogenic medication and documentation of risk acknowledgement. However, there is poor adherence to the prescribed guidelines in clinical practice. Aim: To describe the range of psychotropic medications prescribed to women of reproductive age (WRA) with BD at a tertiary psychiatric unit. Setting: Helen Joseph Hospital, Johannesburg, South Africa. Methods: A retrospective record review of females aged 18-49 years treated for BD between January 2016 and December 2023 was conducted. A convenience sample of 141 files was reviewed. Data were collected from the latest clinical notes and prescription charts. Results: A combination of mood stabilisers (MS) and atypical antipsychotics was predominantly prescribed (81.6%). Of the MS, valproate use was most common (50.6%), followed by lithium (29.3%). Risperidone was the most prescribed antipsychotic (39.0%), followed by olanzapine (24.7%) and quetiapine (20.5%). Antidepressants were combined with MS or antipsychotics in 10.6% of cases. Documented contraception counselling (5%) and contraception use (9.2%) were low. None of the records had documented risk acknowledgement for valproate use (100%). Conclusion: Prescribing guidelines for teratogenic MS were not consistently followed. Therefore, WRA diagnosed with BD may be at an increased risk of teratogenic drug exposure in pregnancy. Contribution: This study highlights the need for improved documentation of medication risk discussions, family planning and informed consent at every visit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.